Proteasome Inhibitors Market Report 2026

The proteasome inhibitors market size has grown strongly in recent years. It will grow from $2.17 billion in 2025 to $2.37 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to approval of first proteasome inhibitors, increasing prevalence of multiple myeloma, rising investment in oncology research, advancements in cancer diagnostics, growth of hospital oncology departments.

The proteasome inhibitors market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to expansion of proteasome inhibitor pipeline, integration of AI in drug discovery, rising demand for combination therapies, development of oral formulations, growth of emerging oncology markets. Major trends in the forecast period include personalized cancer therapies, targeted proteasome inhibition, combination therapy development, improved drug delivery systems, clinical trial expansion.

The rising incidence of pancreatic cancer is expected to drive the growth of the proteasome inhibitors market in the coming years. Pancreatic cancer originates in the cells of the pancreas, an organ located behind the stomach in the abdomen. Proteasome inhibitors are primarily used to treat pancreatic cancer, as the proteasome is essential for cancer cell survival by degrading proteins that regulate the cell cycle and apoptosis. These inhibitors disrupt cancer cell survival, slowing tumor growth and metastasis. For example, according to the American Cancer Society, a US-based health organization, an estimated 64,050 adults in the US were diagnosed with pancreatic cancer in 2023, with 50,550 deaths. By 2024, diagnoses rose to 66,440, with deaths reaching 51,750. The increasing prevalence of pancreatic cancer is therefore fueling demand in the proteasome inhibitors market.

Rising government funding for research and development is also expected to support market growth. Government funding provides financial support for scientific investigations, clinical trials, and drug development, playing a crucial role in advancing proteasome inhibitor research. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a $7.3 billion budget from the United States Congress for fiscal year 2023, an increase of $408 million compared to 2022. Increasing government funding for research is therefore driving growth in the proteasome inhibitors market.

These companies are focusing on developing advanced, ready-to-use formulations to improve treatment efficiency, simplify administration, and enhance patient safety. Ready-to-use injectable products eliminate on-site reconstitution, reducing preparation time, minimizing dosing errors, and streamlining oncology care. For example, in April 2025, Amneal Pharmaceuticals Inc., a US-based specialty pharmaceutical company, launched BORUZU, the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma. This formulation allows direct administration without reconstitution, helping healthcare providers deliver faster and more reliable proteasome inhibitor therapy in outpatient and hospital settings.

Major companies operating in the proteasome inhibitors market are Pfizer Inc., Johnson And Johnson, Onyx Pharmaceuticals Inc., Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Apotex Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, AbbVie, Karyopharm Therapeutics, OncoArendi Therapeutics, Novartis AG, GlaxoSmithKline plc, Sanofi S.A., Eli Lilly and Company.

North America was the largest region in the proteasome inhibitors market in 2025. The regions covered in the proteasome inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proteasome inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the proteasome inhibitors market by increasing the cost of imported active pharmaceutical ingredients and advanced manufacturing equipment, causing delays in production and supply chain disruptions. The hospital pharmacy and specialty clinics segments, particularly in North America and Europe, are most affected due to high reliance on imported drugs. Some domestic manufacturers are benefiting as tariffs encourage local sourcing and production investments, potentially reducing long-term costs and fostering innovation in drug formulations.

The proteasome inhibitors market research report is one of a series of new reports that provides proteasome inhibitors market statistics, including proteasome inhibitors industry global market size, regional shares, competitors with a proteasome inhibitors market share, detailed proteasome inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the proteasome inhibitors industry. This proteasome inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Proteasome inhibitors are a class of drugs that disrupt the function of proteasomes, cellular complexes responsible for regulated protein degradation. These inhibitors are mainly employed in the treatment of specific cancers, particularly multiple myeloma and certain types of lymphoma, showing strong effectiveness in targeting cancer cells and promoting cell death.

The primary products in the proteasome inhibitor category include Velcade, Kyprolis, Ninlaro, and others. Velcade is the brand name for the prescription drug bortezomib, a proteasome inhibitor used to treat multiple myeloma. The category includes drugs such as bortezomib, carfilzomib, and ixazomib, which are applied to treat conditions including lymphoma, mantle cell lymphoma, and multiple myeloma. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with the main end-users being hospitals, specialty clinics, and similar healthcare facilities.

The proteasome inhibitor market consists of sales of marizomib, oprozomib, and delanzomib, epoxyketone proteasome inhibitors, non-peptidic proteasome inhibitors, panobinostat and olaparib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.